



US 20110104183A1

(19) **United States**

(12) **Patent Application Publication**
Berx et al.

(10) **Pub. No.: US 2011/0104183 A1**

(43) **Pub. Date: May 5, 2011**

(54) **USE OF SIPI AS DETERMINANT OF BREAST
CANCER STEMNESS**

Related U.S. Application Data

(60) Provisional application No. 61/067,511, filed on Feb. 27, 2008.

(75) Inventors: **Geert Berx**, Linter-Wommersom (BE); **Cindy Vandewalle**, Gent (BE); **Eric Raspe**, Mouscron (BE)

Publication Classification

(51) **Int. Cl.**
A61K 39/395 (2006.01)
C12Q 1/68 (2006.01)
C12N 5/095 (2010.01)
A61K 31/7105 (2006.01)
G01N 33/574 (2006.01)
A61P 35/00 (2006.01)

(52) **U.S. Cl.** 424/174.1; 435/6; 435/375; 514/44 A; 435/7.23

(73) Assignees: **VIB VZW**, Gent (BE); **UNIVERSITEIT GENT**, Gent (BE)

(21) Appl. No.: **12/735,984**

(22) PCT Filed: **Feb. 26, 2009**

(57) **ABSTRACT**

The present invention relates to the diagnosis and treatment of cancer. More specifically, it relates to the use of SIPI nucleic acid and/or protein for the detection of breast cancer stem cells, and the repression of the gene and/or the inactivation of the protein to repress the differentiation of cells into cancer cells and to inhibit metastasis of breast cancer tumors.



(86) PCT No.: **PCT/EP2009/052304**

§ 371 (c)(1),
(2), (4) Date: **Nov. 16, 2010**

231 control

231 SIP1kd

H/E



SIP1

